Currently browsing all articles within: News
The chemotherapeutic drugs used during stem-cell transplant for high-risk neuroblastoma appear to be changing under the Children’s Oncology Group (COG) protocol.
A new post on the NB Globe website provides a detailed look at MYCN amplification in neuroblastoma and the emergence of a new therapy called BET bromodomain inhibition.
Stand Up to Cancer and St. Baldrick’s have come together to fund the development of a new pediatric cancer dream team.
Josh Cassidy, neuroblastoma warrior and survivor, wins the Boston Marathon in the Men’s Wheelchair Race and beats the world record by a full 2 seconds. He crossed the finish line with a time of 1 hour, 18 minutes and 25 …
A recent article in the Canadian Medical Association Journal examines the difference in opinion between parents and medical professionals when a child fighting cancer does not have a reasonable chance at survival.
The Canadian Cancer Society announced funding for research work being done by Dr. Meredith Irwin at SickKids Hospital in Toronto.
The medical journal “Pediatric Blood and Cancer”, recently published an article on the cost of childhood cancer. Through the lens of a literature review, the paper examined three categories of costs — direct, indirect, and psychosocial costs.
Today, researchers from SickKids Hospital announced their results from recent laboratory research examining the effect of a drug called Imetelstat on telomerase inhibition.
In 2011, Neuroblastoma Canada will formally launch a mentoring program available to Canadian neuroblastoma families and their extended networks. We are now gathering names of people who would like to volunteer their time to be a mentor to a newly diagnosed family. And, if you are looking for mentoring support, please let us know.
A $30 million dollar donation was made today to SickKids by the Garron Family. This incredible act of philanthropy will “support four new research chairs and two clinical scientists, and help in the building of new facilities. But it will also fund clinical trials and develop new treatments for some of the most difficult childhood cancers such as neuroblastoma.”